Immunovant Stock Rises 33.6% to $35.12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Immunovant is up 33.6%, or $8.83 to $35.12.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMVT
Wall Street analysts forecast IMVT stock price to rise
9 Analyst Rating
7 Buy
2 Hold
0 Sell
Strong Buy
Current: 34.150
Low
22.00
Averages
37.00
High
54.00
Current: 34.150
Low
22.00
Averages
37.00
High
54.00
About IMVT
Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Immunovant Stock Hits Five-Year High Following Positive Trial Results
- Successful Clinical Trial: Immunovant's drug candidate IMVT-1402 demonstrated clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 at Week 16 in treating hard-to-treat rheumatoid arthritis, indicating strong efficacy that could drive future regulatory approval and commercialization.
- Significant Stock Surge: Following the trial results, Immunovant's stock soared to a high of $36.28 before closing up 35.26% at $35.56, reflecting investor optimism about the company's prospects and potentially attracting more investor interest.
- Investment Rating Maintained: Investment firm Stifel reiterated its “buy” recommendation and set a price target of $49 for Immunovant, demonstrating confidence in the company's future growth, especially after the successful trial results that are expected to expedite regulatory approval.
- Poor Financial Performance: Despite the positive clinical trial outcomes, Immunovant reported a 38.9% year-over-year increase in net losses to $147.8 million in the first quarter, highlighting high R&D and marketing costs that may affect short-term investment appeal.
See More
IMVT-1402 Phase 2 Data Shows Strong Response Rates
- Clinical Trial Progress: IMVT-1402 demonstrated a 72.7% improvement rate in rheumatoid arthritis patients, with 54.5% showing substantial improvement and 35.8% significant improvement, indicating the drug's potential in treating refractory patients, which is expected to enhance the company's market performance.
- Trial Phase Transition: The trial will move into a blinded second phase to evaluate whether patients can maintain their response through Week 28, and success in this phase will lay the groundwork for further development of IMVT-1402, boosting investor confidence.
- Financial Performance: Immunovant reported a Q4 net loss of $147.9 million, or $0.73 per share, exceeding Wall Street's estimate of $0.63, yet the stock surged 36% due to positive clinical data, reflecting market optimism about its future potential.
- Increased R&D Spending: Research and development expenses rose from $93.7 million last year to $142.3 million, primarily driven by IMVT-1402 clinical trial activities, and while this increase may impact short-term financial performance, it lays the foundation for long-term growth.
See More
Immunovant's Phase 2 Trial Results Show Promising Efficacy for IMVT-1402
- Clinical Trial Results: Immunovant's IMVT-1402 demonstrated a 72.7% ACR20 response rate in its Phase 2 trial for rheumatoid arthritis, indicating significant efficacy in improving patient outcomes and potentially offering new treatment options for difficult-to-treat patients.
- Dose Response Analysis: The open-label phase showed that a weekly injectable dose of 600 mg of IMVT-1402 achieved 54.5% and 35.8% ACR50 and ACR70 responses, respectively, highlighting the drug's strong performance across various efficacy measures and enhancing its market potential.
- Safety Assessment: Immunovant reported no new drug-related safety events during the trial, indicating that IMVT-1402 was well-tolerated among participants, which lays a solid foundation for its future clinical applications.
- Positive Market Reaction: JPMorgan analyst Brian Cheng welcomed the trial results, reiterating his Overweight rating on Roivant, noting that the data exceeded expectations and supports the drug's potential in treating rheumatoid arthritis.
See More
Immunovant Reports Fiscal 2026 Financial Results and Updates on IMVT-1402
- Widening Financial Loss: Immunovant reported a net loss of $147.9 million for Q4 2026, translating to $0.73 per share, which is an increase from a net loss of $106.4 million or $0.64 per share in Q4 2025, indicating pressure from rising R&D costs.
- Increased R&D Expenses: The company’s R&D expenses surged to $142.3 million in Q4 2026, up from $93.7 million a year earlier, primarily driven by activities related to the IMVT-1402 clinical trials, reflecting a strong commitment to drug development despite financial losses.
- Strong Cash Reserves: As of March 31, 2026, Immunovant held $902.1 million in cash and cash equivalents, providing a solid financial runway through the potential launch of IMVT-1402, which is crucial for supporting ongoing clinical trials and market entry.
- Steady Clinical Progress: The development of IMVT-1402 is on track across multiple indications, including ongoing Phase 3 trials for Graves' disease and myasthenia gravis, with topline data expected in 2027, showcasing the company's strategic focus on advancing its lead candidate despite setbacks in other programs.
See More
Immunovant Q4 Earnings Miss Expectations with Significant Cash Reserves
- Earnings Miss: Immunovant reported a Q4 GAAP EPS of -$0.73, missing expectations by $0.13, indicating challenges in profitability that could undermine investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Immunovant's cash and cash equivalents totaled approximately $902.1 million, providing a financial runway for the potential commercial launch of IMVT-1402 and other indications, thereby enhancing its competitive position in the market.
- R&D Setbacks: Despite discussions on the expansion of the Brepocitinib program and updates on Batoclimab Phase III data, the company faced setbacks in late-stage trials for TED therapy, which may hinder future product line development.
- Negative Market Reaction: Following the earnings miss and delays in R&D progress, Immunovant's stock price declined, reflecting market concerns regarding its future growth potential and prompting investors to reassess their investment strategies.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Immunovant Stock Hits Five-Year High Following Positive Trial Results
- Successful Clinical Trial: Immunovant's drug candidate IMVT-1402 demonstrated clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70 at Week 16 in treating hard-to-treat rheumatoid arthritis, indicating strong efficacy that could drive future regulatory approval and commercialization.
- Significant Stock Surge: Following the trial results, Immunovant's stock soared to a high of $36.28 before closing up 35.26% at $35.56, reflecting investor optimism about the company's prospects and potentially attracting more investor interest.
- Investment Rating Maintained: Investment firm Stifel reiterated its “buy” recommendation and set a price target of $49 for Immunovant, demonstrating confidence in the company's future growth, especially after the successful trial results that are expected to expedite regulatory approval.
- Poor Financial Performance: Despite the positive clinical trial outcomes, Immunovant reported a 38.9% year-over-year increase in net losses to $147.8 million in the first quarter, highlighting high R&D and marketing costs that may affect short-term investment appeal.
See More
IMVT-1402 Phase 2 Data Shows Strong Response Rates
- Clinical Trial Progress: IMVT-1402 demonstrated a 72.7% improvement rate in rheumatoid arthritis patients, with 54.5% showing substantial improvement and 35.8% significant improvement, indicating the drug's potential in treating refractory patients, which is expected to enhance the company's market performance.
- Trial Phase Transition: The trial will move into a blinded second phase to evaluate whether patients can maintain their response through Week 28, and success in this phase will lay the groundwork for further development of IMVT-1402, boosting investor confidence.
- Financial Performance: Immunovant reported a Q4 net loss of $147.9 million, or $0.73 per share, exceeding Wall Street's estimate of $0.63, yet the stock surged 36% due to positive clinical data, reflecting market optimism about its future potential.
- Increased R&D Spending: Research and development expenses rose from $93.7 million last year to $142.3 million, primarily driven by IMVT-1402 clinical trial activities, and while this increase may impact short-term financial performance, it lays the foundation for long-term growth.
See More
Immunovant's Phase 2 Trial Results Show Promising Efficacy for IMVT-1402
- Clinical Trial Results: Immunovant's IMVT-1402 demonstrated a 72.7% ACR20 response rate in its Phase 2 trial for rheumatoid arthritis, indicating significant efficacy in improving patient outcomes and potentially offering new treatment options for difficult-to-treat patients.
- Dose Response Analysis: The open-label phase showed that a weekly injectable dose of 600 mg of IMVT-1402 achieved 54.5% and 35.8% ACR50 and ACR70 responses, respectively, highlighting the drug's strong performance across various efficacy measures and enhancing its market potential.
- Safety Assessment: Immunovant reported no new drug-related safety events during the trial, indicating that IMVT-1402 was well-tolerated among participants, which lays a solid foundation for its future clinical applications.
- Positive Market Reaction: JPMorgan analyst Brian Cheng welcomed the trial results, reiterating his Overweight rating on Roivant, noting that the data exceeded expectations and supports the drug's potential in treating rheumatoid arthritis.
See More
Immunovant Reports Fiscal 2026 Financial Results and Updates on IMVT-1402
- Widening Financial Loss: Immunovant reported a net loss of $147.9 million for Q4 2026, translating to $0.73 per share, which is an increase from a net loss of $106.4 million or $0.64 per share in Q4 2025, indicating pressure from rising R&D costs.
- Increased R&D Expenses: The company’s R&D expenses surged to $142.3 million in Q4 2026, up from $93.7 million a year earlier, primarily driven by activities related to the IMVT-1402 clinical trials, reflecting a strong commitment to drug development despite financial losses.
- Strong Cash Reserves: As of March 31, 2026, Immunovant held $902.1 million in cash and cash equivalents, providing a solid financial runway through the potential launch of IMVT-1402, which is crucial for supporting ongoing clinical trials and market entry.
- Steady Clinical Progress: The development of IMVT-1402 is on track across multiple indications, including ongoing Phase 3 trials for Graves' disease and myasthenia gravis, with topline data expected in 2027, showcasing the company's strategic focus on advancing its lead candidate despite setbacks in other programs.
See More
Immunovant Q4 Earnings Miss Expectations with Significant Cash Reserves
- Earnings Miss: Immunovant reported a Q4 GAAP EPS of -$0.73, missing expectations by $0.13, indicating challenges in profitability that could undermine investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Immunovant's cash and cash equivalents totaled approximately $902.1 million, providing a financial runway for the potential commercial launch of IMVT-1402 and other indications, thereby enhancing its competitive position in the market.
- R&D Setbacks: Despite discussions on the expansion of the Brepocitinib program and updates on Batoclimab Phase III data, the company faced setbacks in late-stage trials for TED therapy, which may hinder future product line development.
- Negative Market Reaction: Following the earnings miss and delays in R&D progress, Immunovant's stock price declined, reflecting market concerns regarding its future growth potential and prompting investors to reassess their investment strategies.
See More
